Literature DB >> 26341515

The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool.

Waleed Al-Hamoudi1,2, Faisal Abaalkhail3, Abdurahman Bendahmash4, Naglaa Allam5, Bassem Hegab3, Yasser Elsheikh3, Hamad Al-bahili3, Nasser Almasri3, Mohammed Al-sofayan3, Saleh Alabbad3, Mohammed Al-Sebayel3, Dieter Broering3, Hussien Elsiesy6.   

Abstract

BACKGROUND AND AIMS: Organ shortage has been the ongoing obstacle to expanding liver transplantation worldwide. Living donor liver transplantation (LDLT) is hoped to improve this shortage. The aim of the present study is to analyze the impact of metabolic syndrome and prevalent liver disease on living donations.
METHODS: From July 2007 to May 2012, 1065 potential living donors were evaluated according to a stepwise evaluation protocol. The age of the worked-up donors ranged from 18 to 45 years.
RESULTS: Only 190 (18%) were accepted for donation, and 875 (82%) were rejected. In total, 265 (24.9%) potential donors were excluded because of either diabetes or a body mass index >28. Some potential donors were excluded at initial screening because of incompatible blood groups (115; 10.8%), social reasons (40; 3.8%), or elevated liver enzymes (9; 1%). Eighty-five (8%) donors were excluded because of positive hepatitis serology. Steatosis resulted in the exclusion of 84 (8%) donors. In addition, 80 (7.5%) potential donors were rejected because of variations in biliary anatomy, and 20 (2%) were rejected because of aberrant vascular anatomy. Rejection due to biliary-related aberrancy decreased significantly in the second half of our program (11 vs. 4%, p = 0.001). In total, 110 (10.3%) potential donors were rejected because of insufficient remnant volume (<30%) as determined by CT volumetry, whereas 24 (2.2%) were rejected because of a graft-to-recipient body weight ratio less than 0.8%.
CONCLUSION: Metabolic syndrome and viral hepatitis negatively impacted our living donor pool. Expanding the donor pool requires the implementation of new strategies.

Entities:  

Keywords:  Donor rejection; Living donor liver transplantation; Steatosis; Viral hepatitis

Mesh:

Year:  2015        PMID: 26341515     DOI: 10.1007/s12072-015-9664-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  45 in total

1.  Experience after the evaluation of 700 potential donors for living donor liver transplantation in a single center.

Authors:  Camino Valentín-Gamazo; Massimo Malagó; Marc Karliova; Juergen T Lutz; Andrea Frilling; Silvio Nadalin; Giuliano Testa; Stefan G Ruehm; Yesim Erim; Andreas Paul; Hauke Lang; Guido Gerken; Christoph E Broelsch
Journal:  Liver Transpl       Date:  2004-09       Impact factor: 5.799

2.  Clinical outcomes for Saudi and Egyptian patients receiving deceased donor liver transplantation in China.

Authors:  N Allam; M Al Saghier; Y El Sheikh; M Al Sofayan; H Khalaf; M Al Sebayel; A Helmy; Y Kamel; A Aljedai; H Abdel-Dayem; N M Kenetman; A Al Saghier; W Al Hamoudi; A A Abdo
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

3.  Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors?

Authors:  F M Alswaidi; S J O'Brien
Journal:  J Epidemiol Community Health       Date:  2009-10-12       Impact factor: 3.710

4.  Evaluation of 100 patients for living donor liver transplantation.

Authors:  J F Trotter; M Wachs; T Trouillot; T Steinberg; T Bak; G T Everson; I Kam
Journal:  Liver Transpl       Date:  2000-05       Impact factor: 5.799

5.  Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine.

Authors:  A Jain; M Orloff; P Abt; R Kashyap; R Mohanka; K Lansing; M Kelley; A Bozorgzadeh
Journal:  Transplant Proc       Date:  2005-09       Impact factor: 1.066

6.  Obesity in Saudi Arabia.

Authors:  Mansour M Al-Nozha; Yaqoub Y Al-Mazrou; Mohammed A Al-Maatouq; Mohammed R Arafah; Mohamed Z Khalil; Nazeer B Khan; Khalid Al-Marzouki; Moheeb A Abdullah; Akram H Al-Khadra; Saad S Al-Harthi; Maie S Al-Shahid; Abdulellah Al-Mobeireek; Mohmmed S Nouh
Journal:  Saudi Med J       Date:  2005-05       Impact factor: 1.484

7.  Diabetes mellitus, hypertension and obesity--common multifactorial disorders in Saudis.

Authors:  A S Warsy; M A el-Hazmi
Journal:  East Mediterr Health J       Date:  1999-11       Impact factor: 1.628

8.  Impact of graft size mismatching on graft prognosis in liver transplantation from living donors.

Authors:  T Kiuchi; M Kasahara; K Uryuhara; Y Inomata; S Uemoto; K Asonuma; H Egawa; S Fujita; M Hayashi; K Tanaka
Journal:  Transplantation       Date:  1999-01-27       Impact factor: 4.939

9.  Evolving frequency and outcomes of liver transplantation based on etiology of liver disease.

Authors:  Ashwani K Singal; Praveen Guturu; Bashar Hmoud; Yong-Fang Kuo; Habeeb Salameh; Russell H Wiesner
Journal:  Transplantation       Date:  2013-03-15       Impact factor: 4.939

10.  Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation.

Authors:  Songfeng Yu; Jun Yu; Wei Zhang; Longyu Cheng; Yufu Ye; Lei Geng; Zhiyong Yu; Sheng Yan; Lihua Wu; Weilin Wang; Shusen Zheng
Journal:  J Hepatol       Date:  2014-05-10       Impact factor: 25.083

View more
  6 in total

1.  Evaluating the living donor: expansion by innovation.

Authors:  Chung-Mau Lo
Journal:  Hepatol Int       Date:  2016-02-26       Impact factor: 6.047

2.  Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.

Authors:  Faisal A Abaalkhail; Mohammed I Al Sebayel; Mohammed A Shagrani; Wael A O'Hali; Nasser M Almasri; Abduljaleel A Alalwan; Mohammed Y Alghamdi; Hamad Al-Bahili; Mohammed S AlQahtani; Saleh I Alabbad; Waleed K Al-Hamoudi; Saleh A Alqahtani
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

3.  Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.

Authors:  Khalid Alswat; Abdulrahman A Aljumah; Faisal M Sanai; Faisal Abaalkhail; Mohamed Alghamdi; Waleed K Al Hamoudi; Abdullah Al Khathlan; Huda Al Quraishi; Ahmed Al Rifai; Mohamed Al Zaabi; Mohamed A Babatin; Chris Estes; Almoutaz Hashim; Homie Razavi
Journal:  Saudi J Gastroenterol       Date:  2018 Jul-Aug       Impact factor: 2.485

4.  Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah.

Authors:  Hind Ibrahim Fallatah; Ammar Al-Dabbagh; Mohammead T Hiejazi; Sulaiman A A Hanbazazah; Ali O Hussein; Majed A Al-Sahafi; Hisham O Akbar
Journal:  Saudi J Med Med Sci       Date:  2020-04-17

5.  Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease.

Authors:  Faisal A Alsaif; Sara H Alqahtani; Amani M Alsadoon; Khalid A Alswat; Ayman A Abdo; Mazen M Hassanain; Abdulsalam B Alsharabi; Ghadeer R Aljuhani; Hisham M Alkhalidi; Mohammad S Elsharkawy; Maram A Alotaibi; Faisal M Sanai; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-04-14       Impact factor: 2.485

6.  Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease.

Authors:  Saleh A Alqahtani; Dieter C Broering; Saad A Alghamdi; Khalid I Bzeizi; Noara Alhusseini; Saleh I Alabbad; Ali Albenmousa; Nasreen Alfaris; Faisal Abaalkhail; Waleed K Al-Hamoudi
Journal:  BMC Gastroenterol       Date:  2021-06-01       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.